Cosentyx and kidney problems?

Can Cosentyx cause kidney problems?

Cosentyx (secukinumab) is a monoclonal antibody targeting IL-17A. It is approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Clinical trials and post-marketing reports show kidney problems are rare but reported. Kidney impairment occurred in less than 1% of patients in trials. Renal failure, nephritis, and increased creatinine have appeared in adverse-event databases.

How do kidney problems occur with Cosentyx?

The mechanism is unclear. Some patients develop immune-mediated glomerulonephritis after receiving monoclonal antibodies that alters immune balance. Immune-complex deposition or direct antibody effects on renal tissue may play a role. Data from spontaneous reports suggest these events remain uncommon.

What should patients who have kidney disease do before taking Cosentyx?

Patients with existing kidney disease should discuss risks with their doctor. No formal contraindication exists, but baseline renal function tests are recommended. Monitoring during treatment is advised for patients with prior renal issues.

How long does it take for kidney problems to show up?

Onset timing varies. Some cases appear during treatment or shortly after. Adverse-event reports list onsets ranging from weeks to months. Specific timing statistics are unavailable because data rely on voluntary submissions.

What happens if kidney problems develop during Cosentyx treatment?

If serum creatinine rises or proteinuria develops, doctors may pause or stop Cosentyx. Kidney function recovery often occurs after discontinuation. Supportive care and referral to nephrology may be required.

Why are companies challenging this patent?

Novartis holds the Cosentyx patent family. Competitors have filed inter partes reviews and other challenges. The core patent covering secukinumab expires in 2030. Core patents cover secukinumab until 2030. Core patents cover secukinumab until 2030.